Chemical Engineering @ChemengFiles.Com

Amira Pharmaceuticals, Inc. announced it will present preclinical data on its program of LPA1 receptor antagonist on June 30, 2009 in the summer research conference of the Federation of American Societies for Experimental Biology (FASEB) held in Carefree, Arizona.

The LPA1 receptor is part of the phosphatidic acid path / lisofosfatidilcolina, which among other things is associated with the communication from cell to cell. In recent studies, it has been shown to play a role in fibrotic disease, particularly idiopathic pulmonary fibrosis (IPF).

"Our data not only confirm that this pathway may play a role in fibrotic diseases such as IPF, but in the process of developing an orally available antagonist that could be studied in a human clinical environment," dijoPeppi Prasit, Ph.D., scientific director. "Although much work remains in this program, we are particularly pleased because we believe that this could be a new class of therapy."

Bob Baltera, CEO, added: "Nuestroprograma of LPA1 is particularly important for Amira. The FPI is a disease-centered skills and the opportunity paraAmira dedesarrollar a therapeutic product by marketing without the assistance of a strategic partner. More important Indeed, the FPI is a serious disease with minimally effective therapeutic options for patients today. "